Skip to main content

Table 3 Crude estimates of mortality, length of stay, and organ dysfunction stratified by study period

From: Intensive insulin therapy and mortality in critically ill patients

  Period I
(n = 2,366)
1 Mar 01 to 28 Feb 02
Period II
(n = 3,322)
1 Mar 02 to 30 Jun 03
Period III
(n = 4,786)
1 Jul 03 to 28 Feb 05
P valuea
ICU mortality, n (%) 214 (9.04) 358 (10.78) 465 (9.75) 0.086
OR (95% CI) of ICU mortality 1.00 1.21 (1.01, 1.46) 1.09 (0.92, 1.29)  
Hospital mortality, n (%) 334 (14.12) 522 (15.71) 686 (14.39) 0.157
OR (95% CI) of hospital mortality 1.00 1.13 (0.97, 1.32) 1.02 (0.88, 1.17)  
Patients in ICU <3 days n = 1,296 n = 1,829 n = 2,678  
ICU mortality in patients in ICU <3 days, n (%) 76 (5.86) 128 (7.0) 181 (6.76) 0.428
Hospital mortality in patients in ICU <3 days, n (%) 122/1,174 (9.4) 203/1,829 (11.1) 283/2,678 (10.6) 0.310
Hospital mortality in patients with hypoglycemia <40 mg/dL, n (%) 9/24 (38) 23/53 (43) 41/103 (40) 0.863
Average SOFA score, mean ± SDb 1.65 (2.00) 1.77 (2.09) 1.62 (1.98) <0.01
Maximum SOFA score, mean ± SDb 2.82 (2.85) 2.96 (2.99) 2.74 (2.84) 0.004
  1. aAnalysis of variance or chi-square comparing the three study periods; period I is used as reference. bScores for the Sequential Organ Failure Assessment (SOFA) can range from 0 to 24, with higher scores indicating a higher risk of death. CI, confidence interval; ICU, intensive care unit; OR, odds ratio; SD, standard deviation.
\